Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06480565 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1/2 Trial of ADI-270 in ccRCC

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jun 2026 → Dec 2026
See other at-risk trials from Adicet Therapeutics

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 2026 to Dec 2026v5
  2. Primary completion date: Jun 2025 to Jun 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  3. Start date changed from estimate of Nov 2024 to Dec 12, 2024
    • Study site revised
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2024 to Nov 2024
    • Study sites: 0 to 1
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
Trial Details
NCT Number NCT06480565
Lead Sponsor Adicet Therapeutics
Conditions
(from sponsor)		 Clear Cell Renal Cell Carcinoma
Related terms Carcinoma, Renal Cell
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov